Aquestive Therapeutics (AQST) News
NASDAQ: AQSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AQST news summary
We found 9 recent headlines mentioning Aquestive Therapeutics (AQST): 2 in the past week and 6 in the past 30 days, most often from GlobeNewswire, Nasdaq. AQST is making an outsized move today, down 6.61% at $3.46, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference", was published by GlobeNewswire on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Aquestive Therapeutics headlines
- Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare ConferenceWARREN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful…GlobeNewswire
- Aquestive Therapeutics, Inc. Announces March 16, 2027 PDUFA Goal Date for Anaphylm NDA ResubmissionAquestive Therapeutics, Inc. reported that its investigational product candidate, Anaphylm (dibutepinephrine) sublingual film, is advancing toward a March 16, 2027, PDUFA goal date following FDA…NasdaqAQST, BIO.B
- Aquestive (AQST) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Anaphylm UpdateAquestive Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026. Total revenues decreased to $7.6 million from $12.8 million in the third quarter 2025,…Nasdaq
- Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateWARREN, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful…GlobeNewswire
- Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ETWARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful…GlobeNewswire
- Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA Resubmission(RTTNews) - Aquestive Therapeutics, Inc. (AQST) announced that the U.S.FDA has accepted the resubmission of its New Drug Application for Anaphylm, a sublingual oral film for the treatment of severe…NasdaqAQST, ET
- Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful…GlobeNewswire
- Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmDEER PARK, Ill. and WARREN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing…GlobeNewswireETON, AQST